Empreendimentos Pague Menos

Pharmaceutical Retail And Digital Channels Will Expand Market Reach

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

10 Mar 25

Updated

01 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

73.9%

7D

20.8%

Loading

1Y

73.9%

7D

20.8%

You can edit this narrative until Dec 2 2:05 PM. Then, changes will post as Updates.

Author's Valuation

R$5.56.5% overvalued

AnalystConsensusTarget Fair Value

Shared on 01 Dec 25

Fair value Increased 5.48%

PGMN3: Future Performance Will Reflect Improved Margins And Lower Discount Rate

Analysts have raised their price target for Empreendimentos Pague Menos from R$5.21 to R$5.50, citing slight improvements in revenue growth and profit margin projections. What's in the News A Special or Extraordinary Shareholders Meeting is scheduled for December 12, 2025.

Shared on 17 Nov 25

Fair value Increased 8.63%

PGMN3: Future Performance Will Reflect Modestly Improved Profitability And Lower Discount Rate

Analysts have raised their price target for Empreendimentos Pague Menos from R$4.80 to R$5.21. This reflects modestly improved expectations for growth and profitability.

Shared on 10 Sep 25

Fair value Increased 13%

The upward revision in the Analyst Price Target for Empreendimentos Pague Menos is principally driven by significantly improved consensus revenue growth forecasts and a higher anticipated future P/E multiple, resulting in a new fair value estimate of R$4.80 per share. Valuation Changes Summary of Valuation Changes for Empreendimentos Pague Menos The Consensus Analyst Price Target has significantly risen from R$4.26 to R$4.80.

Shared on 01 May 25

Fair value Increased 14%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 1.84%

AnalystConsensusTarget has increased revenue growth from 9.8% to 10.8%.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 3.54%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 7.05%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 9.37%

AnalystConsensusTarget has decreased revenue growth from 11.5% to 9.8%, increased profit margin from 1.6% to 2.6% and decreased future PE multiple from 14.0x to 8.2x.

AnalystConsensusTarget Fair Value

R$5.5

6.5% overvalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

10.82%

Food and Staples Retail revenue growth rate

0.18%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

20.30%

Calculation

R$544.80m

Earnings '28

x

17.60x

PE Ratio '28

=

R$9.59b

Market Cap '28

R$9.59b

Market Cap '28

/

1.00b

No. shares '28

=

R$9.57

Share Price '28

R$9.57 Share Price '28

Discounted to 2025 @ 20.30% p.a.

=

R$5.50

Fair Value '25